Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
POLICY PAPERS
March 10, 2023
Rigorous, explicit, evidence-informed priority-setting (EIPS) in healthcare is an essential instrument for achieving value for money. Growing pressures on healthcare budgets, combined with the post-COVID-19 fiscal crises and plateauing development assistance for health, make institutionalising EIPS ...
Blog Post
December 20, 2022
Last month, thousands of family planning policymakers, practitioners, researchers, advocates, and funders gathered in Pattaya City, Thailand for four days of learning and exchanging. The conference plenaries centered on the broad importance of family planning in achieving universal health coverage. ...
Blog Post
December 16, 2022
In 2020, we opened our end-of-year review by saying that “Not even Dr. Pangloss could put a positive spin on… a historic dumpster fire of a year.” The next year, we described 2021 as “not quite the best of times, not quite the worst of times”, which seemed like progress. But if we take one lesson fr...
Blog Post
December 15, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Blog Post
December 14, 2022
In this blog, we briefly summarise six worrying trends in how climate finance is being spent, and recommend the GPEDC set up a working group on climate finance, alongside three other recommendations for policy-makers at bilateral and multilateral development agencies; as well as those working on the...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.